Aptagen, LLC
* The secondary structure may not be accurate because of MFOLD limitations on chemistries other than RNA/DNA.
sTN58 (ID# 9385)

2'-F-RNA
CD44
Cells
17.4 nM (reported value)
The binding of the short aptamers to TNBC cells was assessed by streptavidin-biotin-based (colorimetric) and flow cytometric assays by using 5′-end biotinylated or fluorescently labeled aptamers, respectively. The same batch of cells, originally used for the cell-SELEX protocol and for binding analyses with full-length aptamers, was used. Briefly, 2.0 × 105 cells, plated in a clear round-bottom 96-well plate or maintained in suspension for colorimetric and flow cytometric assay, respectively, were incubated in binding buffer consisting of BlockAid supplemented with yeast tRNA and ultrapure salmon sperm DNA, in the absence (mock-treated) or in the presence of aptamers at the indicated concentrations for 10 min at RT.
71.7°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
rGprGprApfCprApfUprApfUprGprApfUprGpfCprAprApfCprGpfUpfUprGpfUprGprGpfUpfCpfCpfCprGpfUpfUpfUprGpfCprApfCpfUpfUpfUprGpfUpfUpfUprApfCprGp

45
13639.6 g/mole
401200 L/(mole·cm)
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Caliendo A, Camorani S, Ibarra LE, Pinto G, Agnello L, Albanese S, Caianiello A, Illiano A, Festa R, Ambrosio V, Scognamiglio G, Cantile M, Amoresano A, Fedele M, Zannetti A, Cerchia L. A novel CD44-targeting aptamer recognizes chemoresistant mesenchymal stem-like TNBC cells and inhibits tumor growth. Bioact Mater. 2025 Apr 25;50:443-460. doi: 10.1016/j.bioactmat.2025.04.027. PMID: 40342488; PMCID: PMC12059597.
Have your aptamer oligo synthesized ORDER
We are always looking for ways to improve. Please tell us what you think.